Objective
to compare the efficacy and safety of standard-dose edoxaban monotherapy with dual antithrombotic therapy (edoxaban + a single antiplatelet agent) in patients with high-risk AF and stable CAD
Study
prospective, multicentre, open label, randomised clinical trial
Population
patients with high-risk AF (CHA2DS2-VASc score ≥2) and stable CAD
Endpoints
net adverse clinical event (composite of all-cause death, stroke, systemic embolic event, myocardial infarction, unplanned urgent revascularisation, major bleeding, and clinically relevant non-major bleeding) at 1-year post randomisation
/medias/687669/25-T003_ChoandKang_01.jpg)
/medias/687672/25-T003_ChoandKang_02.jpg)
Conclusion
in patients with AF and stable CAD, edoxaban monotherapy was associated with a lower risk of a composite outcome of death from any cause, myocardial infarction, stroke, systemic embolism, unplanned urgent revascularisation, or major bleeding or clinically relevant non-major bleeding than dual antithrombotic therapy at 12 months
Cho and Kang et al. NEJM. 2024
